Three US representatives in particular have been very supportive of Huntington's disease legislation and orphan drugs. Another poster suggested that some contact with government officials might be helpful-
H.R.3678 — 114th Congress (2015-2016)
Preserving Access to Orphan Drugs Act of 2015
Sponsor: Rep. Kelly, Mike [R-PA-3] (Introduced 10/01/2015)
Committees: House - Ways and Means, Energy and Commerce
Latest Action: 10/01/2015 Referred to House Energy and Commerce (All Actions)
Thursday, February 12, 2015
Kinzinger introduces legislation providing Social Security, Medicare for Huntington's Disease victims
Singer Woody Guthrie died at age 55 from Huntington’s disease complications
WASHINGTON DC – Wednesday, Congressmen Adam Kinzinger (R-IL) and Bill Pascrell (D-NJ) reintroduced H.R. 842, the Huntington’s Disease Parity Act, bipartisan legislation which would ensure that Social Security and Medicare are available to people with Huntington’s Disease (HD). With bipartisan support from over 100 cosponsors, it is clear that H.R. 842 is critical to tens of thousands of people across the United States battling this rare, fatal, hereditary disease, as well as their families who care for them.
"The Huntington’s Disease Parity Act is instrumental to providing necessary medical access for those impacted by Huntington’s Disease,” said Congressman Kinzinger. “This bipartisan legislation is a targeted solution that will fix an outdated system for a very vulnerable group of people.”
“Huntington’s disease profoundly affects the lives of entire families – emotionally, socially and financially,” said Congressman Pascrell. “This legislation takes the critical step of shortening the wait for Social Security and improving access to Medicare coverage for individuals with HD in order to get those suffering from this devastating disease the care they need.”
“The entire HD community is thankful for the leadership of Congressmen Kinzinger and Pascrell, and for the continued support of all of our original cosponsors" said Louise Vetter, CEO of the Huntington's Disease Society of America. “The reintroduction of the HD Parity Act with such overwhelming bipartisan support gives our families great hope that Congress will finally act to force a revision of the medically inaccurate Social Security Disability guidelines for HD and waive the two-year Medicare waiting period for individuals disabled by HD. These simple changes will ensure that our families will finally have access to the timely care and resources necessary to fight this terrible disease.”
The disease affects 35,000-50,000 Americans, with 175,000-250,000 more people at risk.
Victims suffer from uncontrolled body movements, known as “chorea,” which eventually leave them unable to walk, stand or even speak intelligibly. The disease also causes cognitive difficulty, memory problems, severe depression and, after 15-20 years, death.
Symptoms usually begin to appear in early to mid-adulthood, but can strike as early as 2 years of age or as late as 80 years. There is no cure or treatment for the disease, but carriers of the faulty gene can now be identified by genetic testing, the Hereditary Disease Foundation says.
Chuck Rangel put a comment up on the FDA patient advisory website and these are the co-sponsors of H.R.3678 — 114th Congress (2015-2016), Preserving Access to Orphan Drugs Act of 2015
Cosponsor Date Cosponsored
Rep. Black, Diane [R-TN-6]* 10/01/2015
Rep. Neal, Richard E. [D-MA-1]* 10/01/2015
Rep. Holding, George [R-NC-13]* 10/01/2015
Rep. Rangel, Charles B. [D-NY-13]* 10/01/2015
Rep. Jenkins, Lynn [R-KS-2]* 10/01/2015
Rep. Tiberi, Patrick J. [R-OH-12]* 10/01/2015
Rep. Marchant, Kenny [R-TX-24]* 10/01/2015
Rep. Nunes, Devin [R-CA-22]* 10/01/2015
Rep. Pompeo, Mike [R-KS-4] 10/06/2015
Rep. Kinzinger, Adam [R-IL-16] 10/06/2015
- Forums
- ASX - By Stock
- US Government Represenatives involved with HD and orphan drug legislation
Three US representatives in particular have been very supportive...
Featured News
Add ATH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.5¢ |
Change
0.001(25.0%) |
Mkt cap ! $26.19M |
Open | High | Low | Value | Volume |
0.5¢ | 0.5¢ | 0.5¢ | $27.94K | 6.050M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
47 | 58163299 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 57489001 | 48 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
47 | 58163299 | 0.004 |
75 | 84508146 | 0.003 |
19 | 29345125 | 0.002 |
16 | 81865102 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 57455001 | 47 |
0.006 | 17905330 | 28 |
0.007 | 9788861 | 19 |
0.008 | 8393109 | 16 |
0.009 | 4646078 | 9 |
Last trade - 16.10pm 28/03/2024 (20 minute delay) ? |
|
|||||
Last
0.5¢ |
  |
Change
0.001 ( 0.00 %) |
|||
Open | High | Low | Volume | ||
0.5¢ | 0.5¢ | 0.5¢ | 20524121 | ||
Last updated 15.46pm 28/03/2024 ? |
Featured News
ATH (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online